www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Strive to enable biopharmaceuticals created and
manufactured by China to benefit patients worldwide

List of global drug portfolio

Information is for medical professionals only.

TPIAO (Recombinant human thrombopoietin (rhTPO))

In 2005, TPIAO was listed and has been approved by the CFDA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

Indication Manufacturing base Dosage form & Dosage

Treatment for chemotherapy-induced thrombocytopenia (CIT);
Treatment for immune thrombocytopenia (ITP).

Shenyang manufacturing base

7500 U/1 ml; 15000 U/1 ml

Ruisiyi (Anastrozole)

Ruisiyi is a potent non-steroidal aromatase inhibitor and is suitable for advanced breast cancer that is not controlled by tamoxifen and other anti-estrogen therapies in postmenopausal women. Ruisiyi is the first line drug for breast cancer, showing good tolerance, and it can effectively increase patients’survival. It is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment for advanced breast cancer in postmenopausal women;
Treatment for early-stage breast cancer in postmenopausal women with positive hormone receptor.
Zhejiang manufacturing base 12.5 mg/bottle; 25 mg/bottle

EPIAO (Recombinant human erythropoietin (rhEPO))

In 1998, EPIAO was marketed with approval of the CFDA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment for anemia caused by chronic kidney disease;
Erythrocyte mobilization of peripheral operation;
Treatment for anemia caused by chemotherapy.
Shenyang manufacturing base Penicillin bottle - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece, 36,000 IU/piece;
Pre-filled syringe - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece.

Wanwei (Azasetron Hydrochloride)

Wanwei is a 5-HT3 receptor antagonist antiemetic drug used for vomiting caused by cytotoxic chemotherapy. Wanwei is the first listed generic product among the products of the same type after the original product was approved for import and marketed in China. Compared with other traditional medicines, Wanwei is highly efficient and selective, and can more effectively control delayed vomiting.

Indication Manufacturing base Dosage form & Dosage
Treatment for vomiting caused by cytotoxic chemotherapy; Zhejiang manufacturing base /

Intefen (Recombinant human interferon (α-2a))

In April 1995, Intefen was approved to be manufactured by CFDA.In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata. Shenyang manufacturing base Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml;
Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml.

Inleusin (Recombinant human interleukin2 (IL-2))

In June 1995, CFDA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis. Shenyang manufacturing base 100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle

Etanercept (Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)

Etanercept was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by the CFDA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

Indication Manufacturing base Dosage form & Dosage
Moderate to severe rheumatoid arthritis;
Moderate to severe plaque psoriasis (PS) in adults aged 18 or above;
Active ankylosing spondylitis.
Shanghai manufacturing base 12.5 mg/bottle; 25 mg/bottle

SEPO (Recombinant human erythropoietin (rhEPO))

CFDA production approval documents were obtained for SEPO in 2001. It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce.

Indication Manufacturing base Dosage form & Dosage
Treatment for anemia caused by chronic kidney disease;
Treatment for anemia caused by chemotherapy.
Shenzhen manufacturing base Penicillin bottle - 2000IU/1.0ml/piece, 2500IU/1.0ml/piece, 3000IU/1.0ml/piece, 4000IU/1.0ml/piece, 5000IU/1.0ml/piece, 10000IU/1.0ml/piece;
Pre-filled syringe - 2000IU/0.5ml/piece, 2500IU/0.5ml/piece, 3000IU/0.5ml/piece, 4000IU/0.5ml/piece, 5000IU/0.5ml/piece, 10000IU/0.5ml/piece (PFS).

BYETTA (Exenatide injection)

On October 11, 2016, we have entered into an exclusive license agreement with AstraZeneca to obtain the commercial rights of Byetta and Bydureon in China, which are valid for 20 years.

Indication Manufacturing base Dosage form&Dosage
The product is used to improve the glycemic control in patients with type 2 diabetes, which is suitable for those patients with poor glycemic control after single use of metformin, sulfonylurea or both AstraZeneca China Pen injector of 5 μg dose scale: 0.25 mg/ml, 1.2 ml/piece, single injection of 5 μg, containing injection dose for 60 times;
Pen injector of 10 μg: 0.25 mg/ml, 2.4ml/piece, single injection of 10 μg, containing injection dose for 60 times.

SPARIN (Injectable low-molecular-weight heparin calcium (LMWH-Ca))

SPARIN was approved by the CFDA and listed in 2002. Low-molecular-weight heparin calcium is derived from depolymerization of standard heparin. Compared to standard heparin, low-molecular-weight heparin calcium has the advantages of lower side effects and more predictable anticoagulant response.

Indication Manufacturing base Dosage form & Dosage
The product is used for prophylaxis and treatment of deep vein thrombosis and prevention of clotting during hemodialysis.
Shenzhen manufacturing base /

Mandi (Minoxidil)

Mandi is the first domestically-listed drug among the products of the same type and the first brand the products of the same type at home.

Indication Manufacturing base Dosage form & Dosage
Mandi is used for the treatment of male-pattern alopecia and alopecia areata, and is the first non-prescription drug for hair loss Zhejiang manufacturing base /

Aiyishu (Iron sucrose)

Treatment of iron-deficiency anemia

Indication Manufacturing base Dosage form & Dosage
Treatment of iron-deficiency anemia. Shenyang manufacturing base /

Qiming Keli ()

Qiming Ke Li is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy. It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by the China Food and Drug Administration in 2013. Qiming Ke Li is the first CFDA-approved new Chinese medicine for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.

Indication Manufacturing base Dosage form & Dosage
It’s used for type 2 diabetic retinopathy simplex, TCM differentiation as deficiency of qiyi, deficiency of liver and kidney, eye collaterals and blood stasis, blurred vision, dry eye, fatigued spirit and lack of strength, dysphoria in chestpalms-soles, sweating, thirst with liking for fluids, constipation, soreness and weakness of waist and knees, dizziness and tinnitus. Zhejiang manufacturing base /

Disu (BCG Polysaccharide and Nucleic Acid)

Disu is a new and efficient bidirectional immunomodulator, mainly used for the prevention and treatment of chronic bronchitis, colds and asthma. Disu was included in the National Essential Medicines List.

Indication Manufacturing base Dosage form & Dosage
For the prevention and treatment of chronic bronchitis, colds and asthma. Disu was included in the National Essential Medicines List. Zhejiang manufacturing base /

Jiannipai® (Recombinant humanized anti-CD25 monoclonal antibody injection)

Jiannipai is suitable for prevention of acute rejection after renal transplantation, which can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.

Indication Manufacturing base Dosage form & Dosage
The product is suitable for prevention of acute rejection after renal transplantation, which can be combined with the immunosuppression regime containing calcineurin inhibitors and corticosteroid hormone.
Shanghai manufacturing base 25mg/5ml/vial

Humulin (recombinant insulin)

On May 16, 2017, the Company signed an exclusive license agreement with Lilly China, obtaining the commercialization rights for insulin product Humulin® in China.

Indication Manufacturing base Dosage form & Dosage
Diabetes Lilly China /